Discontinuation of hormone replacement therapy in young GH-treated hypopituitary women increases liver enzymes

Growth Hormone and IGF Research

Volumn 20, Issue 1, 2010, Pages 26-30

  Høst, Christian ^a   Christiansen, Jens J ^a   Christiansen, Jens S ^a   Jorgensen, Jens O L ^a   Gravholt, Claus H ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Estradiol; Hormone replacement therapy; Hypopituitarism; Metabolic syndrome; Non alcoholic fatty liver disease (NAFLD)

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GLUCOSE; GROWTH HORMONE; INSULIN; LEPTIN; LIVER ENZYME; MEDROXYPROGESTERONE; NORETHISTERONE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FAT CONTENT; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOPITUITARISM; IMPEDANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; LIVER METABOLISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOGONADISM; HYPOPITUITARISM; INSULIN; INSULIN RESISTANCE; LEPTIN; LIPIDS; LIVER; OBESITY; WITHHOLDING TREATMENT;

EID: 75049085559     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2009.07.001     Document Type: Article

References (47)

1. Bulow B., Hagmar L., Eskilsson J., and Erfurth E.M. Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. J. Clin. Endocrinol. Metab. 85 2 (2000) 574-584
2. Rosen T., and Bengtsson B.A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336 8710 (1990) 285-288
3. Tomlinson J.W., Holden N., Hills R.K., Wheatley K., Clayton R.N., Bates A.S., et al. Association between premature mortality and hypopituitarism. West midlands prospective hypopituitary study group. Lancet 357 9254 (2001) 425-431
4. Stochholm K., Gravholt C.H., Laursen T., Laurberg P., Andersen M., Kristensen L.O., et al. Mortality and GH deficiency: a nationwide study. Eur. J. Endocrinol. 157 1 (2007) 9-18
5. Markussis V., Beshyah S.A., Fisher C., Parker K.H., Nicolaides A.N., and Johnston D.G. Abnormal carotid arterial wall dynamics in symptom-free hypopituitary adults. Eur. J. Endocrinol. 136 2 (1997) 157-164
6. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (HERS) research group. JAMA 280 7 (1998) 605-613
7. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
8. Rossouw J.E., Prentice R.L., Manson J.E., Wu L., Barad D., Barnabei V.M., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 13 (2007) 1465-1477
9. Turgeon J.L., Carr M.C., Maki P.M., Mendelsohn M.E., and Wise P.M. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies. Endocr. Rev. 27 6 (2006) 575-605
10. Mikkola T.S., and Clarkson T.B. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc. Res. 53 3 (2002) 605-619
11. Prentice R.L., Langer R.D., Stefanick M.L., Howard B.V., Pettinger M., Anderson G.L., et al. Combined analysis of women's health initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am. J. Epidemiol. 163 7 (2006) 589-599
12. Castelo-Branco C., Palacios S., Vazquez F., Villero J., Ferrer J., Ascaso C., et al. Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study. Fertil. Steril. 88 2 (2007) 383-389
13. Shulman L.P. Effects of progestins in different hormone replacement therapy formulations on estrogen-induced lipid changes in postmenopausal women. Am. J. Cardiol. 89 12A (2002) 47E-54E
14. Toda K., Takeda K., Akira S., Saibara T., Okada T., Onishi S., et al. Alternations in hepatic expression of fatty-acid metabolizing enzymes in ArKO mice and their reversal by the treatment with 17beta-estradiol or a peroxisome proliferator. J. Steroid Biochem. Mol. Biol. 79 1-5 (2001) 11-17
15. Nemoto Y., Toda K., Ono M., Fujikawa-Adachi K., Saibara T., Onishi S., et al. Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. J. Clin. Invest. 105 12 (2000) 1819-1825
16. Omoya T., Shimizu I., Zhou Y., Okamura Y., Inoue H., Lu G., et al. Effects of idoxifene and estradiol on NF-kappaB activation in cultured rat hepatocytes undergoing oxidative stress. Liver 21 3 (2001) 183-191
17. Inoue H., Shimizu I., Lu G., Itonaga M., Cui X., Okamura Y., et al. Idoxifene and estradiol enhance antiapoptotic activity through estrogen receptor-beta in cultured rat hepatocytes. Dig. Dis. Sci. 48 3 (2003) 570-580
18. Elsheikh M., Hodgson H.J., Wass J.A., and Conway G.S. Hormone replacement therapy may improve hepatic function in women with Turner's syndrome. Clin. Endocrinol. (Oxf) 55 2 (2001) 227-231
19. Gravholt C.H., Naeraa R.W., Fisker S., and Christiansen J.S. Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner's syndrome, with important modulations by treatment with 17 beta-estradiol. J. Clin. Endocrinol. Metab. 82 8 (1997) 2570-2577
20. Guttmann H., Weiner Z., Nikolski E., Ish-Shalom S., Itskovitz-Eldor J., Aviram M., et al. Choosing an oestrogen replacement therapy in young adult women with Turner syndrome. Clin. Endocrinol. (Oxf) 54 2 (2001) 159-164
21. Gravholt C.H., Poulsen H.E., Ott P., Christiansen J.S., and Vilstrup H. Quantitative liver functions in Turner syndrome with and without hormone replacement therapy. Eur. J. Endocrinol. 156 6 (2007) 679-686
22. McKenzie J., Fisher B.M., Jaap A.J., Stanley A., Paterson K., and Sattar N. Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clin. Endocrinol. (Oxf) 65 1 (2006) 40-44
23. Tarantino G., Saldalamacchia G., Conca P., and Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J. Gastroenterol. Hepatol. 22 3 (2007) 293-303
24. Christiansen J.J., Fisker S., Gravholt C.H., Bennett P., Svenstrup B., Andersen M., et al. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I. Eur. J. Endocrinol. 152 5 (2005) 719-726
25. Lukaski H.C., Johnson P.E., Bolonchuk W.W., and Lykken G.I. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am. J. Clin. Nutr. 41 4 (1985) 810-817
26. Lykkesfeldt G., Bennett P., Lykkesfeldt A.E., Micic S., Moller S., and Svenstrup B. Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X-linked ichthyosis. Clin. Endocrinol. (Oxf) 23 4 (1985) 385-393
27. Frystyk J., Tarnow L., Hansen T.K., Parving H.H., and Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 48 9 (2005) 1911-1918
28. Roulot D., Degott C., Chazouilleres O., Oberti F., Cales P., Carbonell N., et al. Vascular involvement of the liver in Turner's syndrome. Hepatology 39 1 (2004) 239-247
29. Gravholt C.H., Juul S., Naeraa R.W., and Hansen J. Morbidity in Turner syndrome. J. Clin. Epidemiol. 51 2 (1998) 147-158
30. Yahata T., Kurabayashi T., Kato R., Yamamoto Y., Fujimaki T., Yasuda M., et al. Effect of hormone replacement therapy on lipid metabolism in patients with premature ovarian failure and Turner's syndrome. Nippon Sanka Fujinka Gakkai Zasshi 46 11 (1994) 1197-1204
31. Angulo P., and Lindor K.D. Non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 17 Suppl. (2002) S186-S190
32. Pagano G., Pacini G., Musso G., Gambino R., Mecca F., Depetris N., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35 2 (2002) 367-372
33. Vozarova B., Stefan N., Lindsay R.S., Saremi A., Pratley R.E., Bogardus C., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51 6 (2002) 1889-1895
34. Prati D., Taioli E., Zanella A., Della T.E., Butelli S., Del V.E., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 137 1 (2002) 1-10
35. American gastroenterological association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 123(5) (2002) pp.1702-1704.
36. Shimizu I., Kohno N., Tamaki K., Shono M., Huang H.W., He J.H., et al. Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J. Gastroenterol. 13 32 (2007) 4295-4305
37. Mueller M.D., Vigne J.L., Minchenko A., Lebovic D.I., Leitman D.C., and Taylor R.N. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc. Natl. Acad. Sci. USA 97 20 (2000) 10972-10977
38. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrinol. Rev. 25 4 (2004) 581-611
39. LeCouter J., Moritz D.R., Li B., Phillips G.L., Liang X.H., Gerber H.P., et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299 5608 (2003) 890-893
40. Oren R., Zajicek G., Maaravi Y., Kenet G., Karmely F., Hubert A., et al. Methimazole slows hepatocyte streaming in rats. Dig. Dis. Sci. 42 7 (1997) 1433-1437
41. Kanaya A.M., Herrington D., Vittinghoff E., Lin F., Grady D., Bittner V., et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement. Study a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 138 1 (2003) 1-9
42. Pentti K., Tuppurainen M.T., Honkanen R., Sandini L., Kroger H., Alhava E., et al. Hormone therapy protects from diabetes: the Kuopio osteoporosis risk factor and prevention study. Eur. J. Endocrinol. 160 6 (2009) 979-983
43. Salpeter S.R., Walsh J.M., Ormiston T.M., Greyber E., Buckley N.S., and Salpeter E.E. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes. Metab. 8 5 (2006) 538-554
44. Gravholt C.H. Epidemiological, endocrine and metabolic features in Turner syndrome. Eur. J. Endocrinol. 151 6 (2004) 657-687
45. Paquette A., Shinoda M., Rabasa L.R., Prud'homme D., and Lavoie J.M. Time course of liver lipid infiltration in ovariectomized rats: impact of a high-fat diet. Maturitas 58 2 (2007) 182-190
46. Paolisso G., Rizzo M.R., Mone C.M., Tagliamonte M.R., Gambardella A., Riondino M., et al. Plasma sex hormones are significantly associated with plasma leptin concentration in healthy subjects. Clin. Endocrinol. (Oxf) 48 3 (1998) 291-297
47. Shimizu H., Shimomura Y., Nakanishi Y., Futawatari T., Ohtani K., Sato N., et al. Estrogen increases in vivo leptin production in rats and human subjects. J. Endocrinol. 154 2 (1997) 285-292